» Articles » PMID: 39483594

Management of Multiple Fractures in a Preadolescent With Osteogenesis Imperfecta Types III-IV

Overview
Journal Cureus
Date 2024 Nov 1
PMID 39483594
Authors
Affiliations
Soon will be listed here.
Abstract

Osteogenesis imperfecta is an inherited disorder that results in fragile bones that break easily. Gene defects are responsible for the disease. Collagen, a protein that helps strengthen bones, is produced by these genes. The disease can be classified into four types ranging from mild to lethal. Type III or type IV is the most severe forms that survive the neonatal period. In osteogenesis imperfecta strengthening the bone requires correcting the genetic mutations that cause the disorder. Physical rehabilitation, surgical procedures, and clinical management of osteogenesis imperfecta include the use of drugs such as bisphosphonates and recombinant human growth hormone. A nine-year-old male child came to the radiology department with a clinical history of bony deformities of both legs since the age of six years. The child was normal until the age of six years. Then, later, he had a right femur fracture. Surgery was done with a rod inserted in his femur, which was later removed, causing bending of his tibia and fibula. Treatment can improve the quality of life and manage symptoms, but the condition cannot be cured. As part of the treatment, bone-strengthening medications, physiotherapy, and surgery may be required.

References
1.
Rauch F, Travers R, Parfitt A, Glorieux F . Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000; 26(6):581-9. DOI: 10.1016/s8756-3282(00)00269-6. View

2.
Palomo T, Vilaca T, Lazaretti-Castro M . Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2017; 24(6):381-388. DOI: 10.1097/MED.0000000000000367. View

3.
Imbert L, Auregan J, Pernelle K, Hoc T . Mechanical and mineral properties of osteogenesis imperfecta human bones at the tissue level. Bone. 2014; 65:18-24. DOI: 10.1016/j.bone.2014.04.030. View

4.
Forlino A, Marini J . Osteogenesis imperfecta. Lancet. 2015; 387(10028):1657-71. PMC: 7384887. DOI: 10.1016/S0140-6736(15)00728-X. View

5.
Alcausin M, Briody J, Pacey V, Ault J, McQuade M, Bridge C . Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013; 79(6):333-40. DOI: 10.1159/000351374. View